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estimated opportunity loss due to uncertainty, compared with the situation in 
which the evidence was synthesized using traditional pairwise meta-analysis. 
The nominal value of EVPIs varied considerably between the two schemes, with 
potential to have an impact on the justifiability and the optimal sample size of 
the future RCT.  
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OBJECTIVES: In cost-effectiveness literature, several Markov models with 
different health states and assumptions are used to estimate cost-effectiveness 
for treatment of advanced breast cancer (ABC). This study aims to (1) derive the 
relationships among the Markov models for ABC, and (2) examine the impact of 
using different Markov models on cost-effectiveness results for treatment of 
HER2-positive advanced breast cancer. METHODS: There are four Markov models 
for ABC: (i) model 1 includes 4 health states (stable, response, progression, and 
dead) with a possibility of death can occur in all health states; (ii) model 2 also 
consists of 4 health states but the chance of dying can only occur at disease-
progression state; (iii) model 3 is the most common model and has 3 health 
states (stable, progression, and dead) with a possibility of death can occur in all 
health states; and (iv) model 4 also has 3 health states but the chance of death 
can only occur at disease-progression state. Relationships of transition 
probabilities among the Markov models were derived. A simulation method was 
used to generate 10,000 samples with transition probabilities, estimated costs 
and utilities for each health state based on a previously published cost-
effectiveness study of lapatinib in treatment of HER2-positive advanced breast 
cancer. RESULTS: Markov models 2 and 4 yielded similar and lowest incremental 
cost-effectiveness ratios (ICER), while the commonly used Markov model (model 
3) produced the highest ICER. All four Markov models produced ICERs > $150,000 
per additional quality-adjusted life year gained for the combination therapy with 
lapatinib as compared to monotherapy with capecitabine. CONCLUSIONS:  
This study suggests that modeling advanced breast cancer with different health-
state Markov models may produce different cost-effectiveness results. 
Combination therapy with lapatinib in treatment of HER2-positive advanced 
breast cancer is not a cost-effective treatment strategy regardless which Markov 
models used.  
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OBJECTIVES: Economic modeling and health care cost analyses are used to 
inform policy-makers in health care decision-making such as cost-of-illness 
assessments, treatment evaluation studies, and more commonly to predict 
health care costs for specific patient populations. However, due to stochastic 
error distribution assumptions and the challenges they create for econometric 
modeling, various types of models have been identified to address specific 
distributional characteristics. The objective of study is to examine cost 
distributions for treated diabetes patients and compare untransformed ordinary 
least squares (OLS) regression with log transformed OLS and generalized linear 
model (GLM) methods. METHODS: A simulated distribution was created 
mirroring a representative claims dataset for type 2 diabetes costs. Using 
simulated cost distributions with known error term ensures that model selection 
could be assessed with certainty of the error specification for the distribution. 
Two simulated cost distributions were generated: one with homoskedastic errors 
and the other with heteroskedastic errors. Both distributions were used to 
explore model performance under varying conditions. Several tests for model fit, 
specification, and predictive ability were selected from the existing literature to 
assess model selection and determine best model fit. Simulation and all analyses 
were done using STATA 11. RESULTS: Results from the model specification tests 
indicate that for both cost error distributions, OLS regression on untransformed 
Y is the best-fitting model of the three tested. Although superior in model fit, 
prediction criteria indicate that OLS is relatively poor in prediction along the 
entire range of costs. CONCLUSIONS: OLS on untransformed Y cost model is 
selected as the best model choice under the conditions of the given distributions. 
The inability for all three models to predict within the full range of costs 
demonstrates weakness in characterizing the upper tail of the distribution. If 
prediction is the primary concern, a two-part model may be more appropriate.  
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OBJECTIVES: When modeling long-term costs and health effects using Markov 
models, choosing the time of transition to another state (progression of the 
disease) seems to influence the final results. Various approaches can be adopted, 
i.e. transitions at the beginning, at the end or in the middle of the cycle. Our aim 
is to measure influence of cycle length and progression rates on differences 
between final results obtained using those methods and to establish whether 
there is an optimal cycle length for which half cycle correction (HCC) should 
always be applied. METHODS: A simple, hypothetical, two-state Markov model 
was built. The time horizon was set to be lifetime, an outcome discount rate was 
0% or 5% and costs/utilities were held constant in time. Assuming different 
progression rates (0.05–0.90 annually), three methods were compared: transitions 
at the beginning of the cycle (‘beginning’), at the end of the cycle (‘end’), in the 
middle of the cycle (HCC). For each parameter the threshold values were 
determined, i.e. the maximal cycle length for which the difference between half-
cycle correction and ’beginning’/‘end’ methods were not greater than 5%. We 
assumed that cycles longer than the estimated threshold will imply the 
application of HCC. RESULTS: For 5% discount rate the threshold cycle length 
was 1 year for annual progression of 0.05 and it became shorter for lower 
progression rates (2 weeks for 0.90 progression rate). Assuming no discounting, 
the threshold was 2 years for annual progression of 0.05 and 2 weeks for 
progression of 0.90. CONCLUSIONS: Choice of the time of transitions in the 
model may have a significant impact on results. For cycles shorter than 2 weeks 
HCC does not seem to be necessary, however it should always be applied for 
cycles longer than 1 year. For cycles between 2 weeks and 1 year a general 
recommendation cannot be made.  
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OBJECTIVES: Health Technology Assessment (HTA) has during the last decades 
become an increasingly important tool for the introduction of new health care 
interventions. The aim of HTA is to assist payers in making informed decisions 
about allocating resources in the health care system. The use of decision-
analytic modelling (DAM) to aid HTA represents an explicit approach to 
synthesizing available evidence and provides support in reimbursement 
decisions under conditions of uncertainties. Probabilistic sensitivity analysis 
(PSA) is generally viewed as the most appropriate method of handling parameter 
uncertainty as it provides assessment of the joint effect of uncertainty over all 
ingoing parameters. It also facilitates value-of-information analysis that can 
quantify the implications of decision uncertainty explicitly and investigate the 
value of further studies. The objective of this study is to explore the value given 
to probabilistic decision modelling in the context of health technology 
assessment in England and Scandinavia. METHODS: A systematic search was 
undertaken to identify the current guidelines of the HTA bodies in England and 
Scandinavia (Sweden, Norway, and Denmark), specifically extracting all 
information relating to approaches of assessing uncertainties in DAM and the 
request for probabilistic analysis (e.g. incremental net benefit (INB) analysis or 
expected-value-of-perfect-information methods (EVP(P)I). RESULTS: All the 
reviewed HTA agencies and reimbursement authorities require deterministic 
sensitivity analysis for primary assumptions whereas only two agencies 
specifically require an addition of a PSA. The guidelines from the National 
Institute for health and Clinical Excellence (NICE) in the UK express strong 
support of conducting PSA, but have no requirements for the inclusion of EVP(P)I. 
The Norwegian Medicines Agency (NoMA) guidelines mentions both INB analysis 
and EVP(P)I. The remaining countries have no specific requirements regarding 
probabilistic modelling at all. CONCLUSIONS: The recent inclusion 
recommendations of INB and EVP(P)I in Norway indicate a growing recognition of 
the value of probabilistic analysis.  
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OBJECTIVES: Unlike modeling chronic diseases such as diabetes, ILS for oncology 
drugs health technology assessment (HTA) is rare because of short treatment 
duration, simple disease states and treatment pathways. With new drugs filling 
the space of mild symptomatic or asymptomatic cancer patients, researchers 
start to embrace the method of ILS because it can better predict survival and 
other events by individual patient tracking, and simulate trials and real world 
clinical practice. It has not been widely endorsed by HTA payers due to lack of 
simplicity and transparency. The objective of this study is to review and catalog 
different modeling methods used in NICE submissions for advanced/metastatic 
cancer treatments, understand when NICE is looking for ILS. METHODS: A 
targeted search of NICE website found 68 NICE rulings happened between 2000 
and 2012 for oncology drugs. We extracted information on the model used, the 
application setting, the method and data used to model cancer evolution. 
RESULTS: Survival trees and Markov cohort models were most commonly 
employed. Simulation methods evolved from simple decision trees to more 
complex Markov models over the last decade. ILS model was submitted to NICE 
for decision making by manufacturers. NICE stated that it would accept the 
discrete event simulation model, a type of ILS, if manufacturer made a well 
justified case. When multiple treatments and/or patient heterogeneity exist, and 
such complexity influences cost and health outcomes, NICE encouraged the 
method of ILS. For example, ILS was suggested in modeling the first line 
maintenance of Rituximab in treating the stage III-IV follicular lymphoma and 
first line treatment of Imatinib in treating metastatic gastro-intestinal stromal 
tumors. CONCLUSIONS: ILS emerges as a modeling method for cancer treatment 
because it provides a framework for natural representation of disease and 
resource use. Although it is a more sophisticated approach, some HTAs like NICE 
start to support this method.  
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